BTBP(600161)2025-04-25 11:10Financial Performance - The company's operating revenue for Q1 2025 was CNY 1,317,766,404.91, representing a 7.84% increase compared to CNY 1,221,955,159.91 in the same period last year[4] - Net profit attributable to shareholders decreased by 22.90% to CNY 244,145,675.45 from CNY 316,673,978.07 year-on-year[4] - Basic and diluted earnings per share both decreased by 22.90% to CNY 0.12 from CNY 0.16 in the same period last year[4] - The net profit for the first quarter of 2025 was CNY 337,283,020.12, a decrease of 22% from CNY 432,127,203.32 in the first quarter of 2024[22] - The company reported a total profit of CNY 406,278,490.58 for the first quarter of 2025, down 21.3% from CNY 516,222,287.60 in the first quarter of 2024[21] Cash Flow - The net cash flow from operating activities was negative at CNY -301,639,713.20, a decline of 164.34% compared to CNY 468,822,105.59 in the previous year[4] - The net cash flow from operating activities for the first quarter of 2025 was negative CNY 301,639,713.20, compared to positive CNY 468,822,105.59 in the first quarter of 2024[25] - Cash and cash equivalents at the end of the first quarter of 2025 were CNY 1,009,596,840.81, down from CNY 2,516,181,677.81 at the end of the first quarter of 2024[26] - The net cash inflow from investment activities was 96,576,284.63, while the net cash outflow was 627,560,430.00, resulting in a net cash flow of -530,984,145.37 from investment activities[33] - The cash flow from investment activities was significantly negative, indicating a potential need for strategic reassessment[33] Assets and Liabilities - Total assets increased by 2.31% to CNY 16,235,343,799.62 from CNY 15,869,522,217.56 at the end of the previous year[5] - Current assets as of March 31, 2025, totaled RMB 8,054,263,131.79, up from RMB 7,722,300,180.61 as of December 31, 2024[14] - Total liabilities were reported at RMB 1,364,862,198.88, slightly up from RMB 1,336,323,636.94, showing an increase of 2.1%[16] - The company's equity attributable to shareholders reached RMB 11,382,850,030.26, an increase from RMB 11,138,704,354.81, reflecting a growth of 2.2%[16] - Total current liabilities increased to CNY 22,702,419.88 as of March 31, 2025, from CNY 11,235,450.23 on December 31, 2024, marking an increase of approximately 102.0%[28] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 74,179[10] - The largest shareholder, China National Biotechnology Group Corporation, holds 45.64% of the shares, totaling 902,500,488 shares[10] Operational Changes - The company is implementing new sales credit policies, which have led to a significant decrease in cash flow from operating activities[8] - The company plans to implement new accounting standards starting from 2025, which may affect the financial statements[33] Research and Development - The company incurred research and development expenses of CNY 30,297,221.48 in the first quarter of 2025, an increase of 23.5% from CNY 24,452,750.69 in the same period of 2024[21] Other Income and Expenses - The company reported other income of CNY 182,640.61 in Q1 2025, compared to CNY 111,548.33 in Q1 2024, reflecting an increase of approximately 63.9%[30] - The company's financial expenses showed a significant improvement, with a net income of CNY -1,463,790.52 in the first quarter of 2025 compared to CNY -14,434,224.27 in the same period of 2024[21]